Lantheus Appoints Julie Eastland as New Board Member
Lantheus Holdings, Inc. (NASDAQ: LNTH), a leading radiopharmaceutical company, has appointed Julie Eastland to its Board of Directors, effective September 3, 2024. Ms. Eastland, an experienced biotechnology and financial executive, will serve as an independent director and member of the Board's Audit Committee. With her addition, the Board now comprises ten directors, eight of whom are independent.
Ms. Eastland brings extensive expertise in finance, strategic planning, operations, and transactions within the biotechnology sector. She currently serves on the boards of Dynavax Technologies and Veana Therapeutics. Her previous roles include CEO of Harpoon Therapeutics and executive positions at ReCode Therapeutics, Rainier Therapeutics, and Cascadian Therapeutics.
Lantheus Holdings, Inc. (NASDAQ: LNTH), una delle principali aziende di radiofarmaceutici, ha nomina Julie Eastland nel proprio Consiglio di Amministrazione, con effetto dal 3 settembre 2024. La signora Eastland, un'esperta nel campo della biotecnologia e della finanza, svolgerà il ruolo di amministratore indipendente e membro del Comitato di Revisione del Consiglio. Con il suo ingresso, il Consiglio ora conta dieci membri, otto dei quali sono indipendenti.
La signora Eastland porta con sé una vasta esperienza in finanza, pianificazione strategica, operazioni e transazioni nel settore biotecnologico. Attualmente è membro dei consigli di amministrazione di Dynavax Technologies e Veana Therapeutics. Le sue esperienze passate includono il ruolo di CEO di Harpoon Therapeutics e posizioni dirigenziali presso ReCode Therapeutics, Rainier Therapeutics e Cascadian Therapeutics.
Lantheus Holdings, Inc. (NASDAQ: LNTH), una empresa líder en radiofármacos, ha nombrado a Julie Eastland en su Junta Directiva, con efecto a partir del 3 de septiembre de 2024. La Sra. Eastland, una experimentada ejecutiva en biotecnología y finanzas, servirá como directora independiente y miembro del Comité de Auditoría de la Junta. Con su incorporación, la Junta ahora está compuesta por diez directores, de los cuales ocho son independientes.
La Sra. Eastland aporta una amplia experiencia en finanzas, planificación estratégica, operaciones y transacciones dentro del sector biotecnológico. Actualmente es miembro de las juntas de Dynavax Technologies y Veana Therapeutics. Sus roles anteriores incluyen CEO de Harpoon Therapeutics y puestos ejecutivos en ReCode Therapeutics, Rainier Therapeutics y Cascadian Therapeutics.
Lantheus Holdings, Inc. (NASDAQ: LNTH), 선도적인 방사성 의약품 회사가 이사회에 줄리 이스트랜드를 임명했습니다, 2024년 9월 3일부터 효력이 발생합니다. 이스트랜드 여사는 생명공학 및 금융 분야에서 풍부한 경험을 가진 전문가로, 독립 이사이자 이사회의 감사위원회의 구성원으로 활동하게 됩니다. 그녀의 추가로 이사회는 현재 10명의 이사로 구성되어 있으며, 그 중 8명이 독립 이사입니다.
이스트랜드 여사는 생명공학 분야에서 재무, 전략적 계획, 운영 및 거래에 대한 폭넓은 전문성을 제공합니다. 현재 그녀는 다이나백스 테크놀로지스와 베아나 테라퓨틱스의 이사회에서 활동하고 있습니다. 그녀의 이전 역할에는 하프룬 테라퓨틱스의 CEO와 레코드 테라퓨틱스, 레이니어 테라퓨틱스 및 카스카디안 테라퓨틱스의 임원 직위가 포함됩니다.
Lantheus Holdings, Inc. (NASDAQ: LNTH), une société de premier plan dans le domaine des radio-pharmaceutiques, a nommé Julie Eastland à son Conseil d'Administration, à compter du 3 septembre 2024. Mme Eastland, une dirigeante expérimentée dans le secteur de la biotechnologie et des finances, agira en tant que directrice indépendante et membre du Comité d'Audit du Conseil. Avec son ajout, le Conseil se compose désormais de dix administrateurs, dont huit sont indépendants.
Mme Eastland apporte une vaste expertise en finances, planification stratégique, opérations et transactions dans le secteur biopharmaceutique. Elle siège actuellement aux conseils d'administration de Dynavax Technologies et Veana Therapeutics. Ses précédents postes incluent celui de PDG de Harpoon Therapeutics et des postes de direction chez ReCode Therapeutics, Rainier Therapeutics et Cascadian Therapeutics.
Lantheus Holdings, Inc. (NASDAQ: LNTH), ein führendes Unternehmen im Bereich der Radiopharmazeutika, hat Julie Eastland in seinen Vorstand berufen, mit Wirkung zum 3. September 2024. Frau Eastland, eine erfahrene Führungskraft im Bereich Biotechnologie und Finanzen, wird als unabhängige Direktorin und Mitglied des Prüfungsausschusses des Vorstands tätig sein. Mit ihrem Eintritt hat der Vorstand nun zehn Direktoren, von denen acht unabhängig sind.
Frau Eastland bringt umfangreiche Fachkenntnisse in Finanzen, strategischer Planung, Betrieb und Transaktionen im Biotechnologiesektor mit. Derzeit ist sie Mitglied der Vorstände von Dynavax Technologies und Veana Therapeutics. Zu ihren bisherigen Positionen gehört die CEO-Position bei Harpoon Therapeutics sowie leitende Funktionen bei ReCode Therapeutics, Rainier Therapeutics und Cascadian Therapeutics.
- Appointment of an experienced biotechnology and financial executive to the Board of Directors
- Expansion of the Board to 10 members, with 8 independent directors
- Addition of expertise in finance, strategic planning, operations, and transactions to support company growth
- None.
BEDFORD, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced the appointment of Julie Eastland, an experienced biotechnology and financial executive, to Lantheus’ Board of Directors (“Board”), effective as of September 3, 2024. As an independent director, Ms. Eastland will serve as a member of the Board’s Audit Committee. Following the appointment of Ms. Eastland, the Board will be comprised of ten directors, eight of whom are independent.
“We are thrilled to welcome Julie Eastland to the Lantheus Board of Directors. Ms. Eastland’s extensive biotechnology expertise across finance, strategic planning, operations and transactions will be invaluable as we continue to grow and innovate,” said Mary Anne Heino, Chairperson of the Board of Lantheus. “Ms. Eastland’s proven track record of driving financial success and strategic initiatives aligns with our vision for the future and I am confident that Ms. Eastland’s insights and leadership will play a crucial role in guiding our company’s leadership in radiopharmaceuticals.”
“I am excited to join the Lantheus Board and work with such a talented and experienced team to support the company’s future initiatives,” said Ms. Eastland. “With its strong commitment to innovation and operational excellence, I am confident that we will continue to make significant strides in improving patient care and enhancing the lives of those we serve.”
Ms. Eastland is currently an independent director and chair of the audit committee of Dynavax Technologies Corporation (NASDAQ: DVAX) and an independent director of Veana Therapeutics, a privately held company. Ms. Eastland served as the Chief Executive Officer of Harpoon Therapeutics, a publicly traded company, from November 2021, and a member of its Board of Directors from October 2018, until its acquisition by Merck Sharpe & Dohme in March of 2024. Ms. Eastland previously served as Chief Operating Officer and Chief Financial Officer of ReCode Therapeutics, a privately-held genetics medicine company focused on delivery of novel, anti-viral lipid nanoparticles therapeutics for respiratory diseases. Prior to ReCode, she served as Chief Financial Officer and Chief Business Officer of Rainier Therapeutics; a private biopharmaceutical company focused on targeting FGFR3 in bladder cancer. Before Rainier, she was Chief Financial Officer and Chief Business Officer of Cascadian Therapeutics, a publicly traded company acquired by Seattle Genetics in 2018. Prior to Cascadian, Ms. Eastland served as Chief Financial Officer and Vice President of Finance and Operations of VLST Corporation, a privately held biotechnology company, and held various financial and strategic management positions at publicly traded biotechnology companies including Dendreon and Amgen. Ms. Eastland received an M.B.A. from Edinburgh University Management School and a B.S. in finance from Colorado State University.
About Lantheus
Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices Canada and Sweden, Lantheus has been providing radiopharmaceutical solutions for more than 65 years. For more information, visit www.lantheus.com.
Safe Harbor for Forward-Looking and Cautionary Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to risks and uncertainties and are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by their use of terms such as “continue,” “execute,” “will” and other similar terms. Such forward-looking statements are based upon current plans, estimates and expectations that are subject to risks and uncertainties that could cause actual results to materially differ from those described in the forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation that such plans, estimates and expectations will be achieved. Readers are cautioned not to place undue reliance on the forward-looking statements contained herein, which speak only as of the date hereof. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law. Risks and uncertainties that could cause our actual results to materially differ from those described in the forward-looking statements are discussed in our filings with the Securities and Exchange Commission (including those described in the Risk Factors section in our Annual Reports on Form 10-K and our Quarterly Reports on Form 10-Q).
Contacts:
Lantheus
Mark Kinarney
Vice President, Investor Relations
978-671-8842
ir@lantheus.com
Melissa Downs
Senior Director, External Communications
646-975-2533
media@lantheus.com
FAQ
Who is the new Board member appointed by Lantheus (LNTH)?
What positions will Julie Eastland hold on Lantheus' (LNTH) Board?
How many directors are on Lantheus' (LNTH) Board after Julie Eastland's appointment?
What is Julie Eastland's background and experience relevant to Lantheus (LNTH)?
